依洛尤单抗联合依折麦布治疗老年冠心病合并高脂血症患者的疗效及对血脂水平的影响

doi:10.3969/j.issn.1671-7171.2026.07.013

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1207 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of evolocumab and ezetimibe and their influences on blood lipid levels in elderly patients with coronary heart disease (CHD) combined with hyperlipidemia. 【Methods】 A total of 152 elderly patients with CHD and hyperlipidemia admitted to our hospital from March 2023 to February 2024 were enrolled and divided into observation group and control group by random number table, with 76 cases in each group. The control group received ezetimibe on the basis of routine treatment, while the observation group was additionally given evolocumab combined with ezetimibe. The clinical efficacy, carotid ultrasound indicators, incidence of adverse reactions and laboratory parameters including low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), soluble intercellular adhesion molecule-1 (sICAM-1), N-terminal pro-brain natriuretic peptide (NT-proBNP) and homocysteine (Hcy), procalcitonin (PCT) were compared between the two groups. 【Results】 After treatment, the total effective rate of the observation group was 97.37% (74/76), which was higher than 88.16% (67/76) of the control group (P<0.05). The serum levels of LDL-C, TC, TG, sICAM-1, NT-proBNP, Hcy and PCT in both groups decreased after treatment, and the observation group showed significantly lower levels than the control group (P<0.05). Carotid intima-media thickness and plaque area were reduced, and the number of plaques decreased in both groups after treatment; the observation group had thinner intima-media thickness, smaller plaque area and fewer plaques compared with the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusions】 Combined therapy of evolocumab and ezetimibe can effectively reduce blood lipid levels, improve vascular endothelial and cardiac function with favorable safety profile in elderly patients with coronary heart disease complicated with hyperlipidemia.

Key words： Coronary Heart Disease Hyperlipidemias Antibodies,Monoclonal Ezetimibe

Received: 22 April 2025

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TANG Enming
	TAO Lewei
	CHEN Wenzhe

Cite this article:

TANG Enming,TAO Lewei,CHEN Wenzhe. Efficacy of Evolocumab Versus Ezetimibe in the Treatment of Elderly Patients with Coronary Heart Disease Complicated with Hyperlipidemia[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(7): 1101-1104.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.07.013 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I7/1101

[1] HONG S J, LEE Y J, LEE S J, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial[J].JAMA,2023,329(13):1078-1087.
[2] DOI T, LANGSTED A, NORDESTGAARD B G. Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction[J].J Am Coll Cardiol,2022,79(24):2383-2397.
[3] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(6):553-578.
[4] DAS P A, GLYNN R J, FRUCHART J C, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk[J].N Engl J Med,2022,387(21):1923-1934.
[5] LEE Y J, CHO J Y, YOU S C, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial[J].Eur Heart J,2023,44(11):972-983.
[6] O'DONOGHUE M L, GIUGLIANO R P, WIVIOTT S D, et al.Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J].Circulation,2022,146(15):1109-1119.
[7] 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华心血管病杂志编辑委员会. 超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J].中华心血管病杂志,2020,48(4):280-286.
[8] ZHANG J H, GONG Y, PENG J, et al. Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia[J].Am J Transl Res,2023,15(5):3403-3409.
[9] GUPTA K, HIRSCH J R, KALSI J, et al. Highlights of cardiovascular disease prevention studies presented at the 2022 American Heart Association Scientific Sessions[J].Curr Atheroscler Rep,2023,25(1):31-41.
[10] ZHANG Y, DRON J S, BELLOWS B K, et al. Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease[J].Circulation,2023,147(20):1556-1559.
[11] NAKANO T,INOUE I,TAKENAKA Y, et al.Ezetimibe promotes brush border membrane-to-lumen cholesterol efflux in the small intestine[J].PLoS One,2016, 11(3):e0152207.
[12] LEE S H, LEE Y J, HEO J H, et al. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis[J].J Am Coll Cardiol,2023,81(14):1339-1349.
[13] 刘东华, 李祥鹏, 徐龙, 等.新型降脂药PCSK9抑制剂依洛尤单抗的研究进展[J].中国药房,2020, 31(23):2938-2944.
[14] 张铭.同型半胱氨酸对血管内皮细胞的氧化应激损伤及对IL-8分泌的影响[D].成都:四川大学,2005.
[15] BRABENEC L,HELLENTHAL K E M,MÜLLER M, et al. Procalcitonin mediates vascular dysfunction in obesity[J].Life Sci,2022, 307: 120889.
[16] ZINELLU A, MANGONI A A.A systematic review and meta-analysis of the effect of statin treatment on sVCAM-1 and sICAM-1[J].Expert Rev Clin Pharmacol,2022, 15(5):601-613.
[17] OMLAND T, PERSSON A, NG L, et al.N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes[J].Circulation,2002, 106(23):2913-2918.